Lipigon Pharmaceuticals AB Company Description

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden.

The company’s product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome.

Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia.

The company was incorporated in 2010 and is based in Umeå, Sweden.

Lipigon Pharmaceuticals AB (publ)

Country	Sweden
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Stefan Nilsson

Contact Details

Address: TvistevAegen 48 C Umeå, 90736 Sweden
Phone	46 7 05 78 17 68
Website	lipigon.se

Stock Details

Ticker Symbol	LPGO
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0015382072
SIC Code	2834

Key Executives

Name	Position
Dr. Stefan K. Nilsson	Co-Founder and Chief Executive Officer
Lars Öhman	Business Development Manager and Chairman
Hugo Petit	Chief Financial Officer